Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study
| Autor: | M. Corona, T. Falbo, M. R. Restuccia, C. Nardoni, A. Rozzi, G. Lanzetta |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Male medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment non-small cell lung cancer (NSCLC) Drug Administration Schedule Carboplatin chemistry.chemical_compound Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Survival rate Aged Neoplasm Staging Pharmacology Aged 80 and over Chemotherapy business.industry Age Factors Combination chemotherapy medicine.disease Surgery Survival Rate Regimen Infectious Diseases Treatment Outcome chemistry Tolerability Disease Progression Female business Febrile neutropenia |
| Zdroj: | Journal of chemotherapy (Florence, Italy). 22(6) |
| ISSN: | 1973-9478 |
| Popis: | Single-agent chemotherapy is the preferred treatment option in chemonaive elderly patients with advanced nonsmall-cell lung cancer (NSCLC). The role of combination chemotherapy in this setting is uncertain although several studies report satisfactory efficacy and safety using weekly paclitaxel and carboplatin (AUC=6) as first-line chemotherapy in elderly patients. It is still unclear which schedule of this regimen which could offer the best therapeutic index. The aim of this study was to evaluate the activity and tolerability of concomitant weekly administration of paclitaxel and carboplatin in untreated elderly patients with advanced NSCLC. From february 2005 to April 2008 36 consecutive elderly patients with advanced NSCLC were enrolled. Median age was 74 years (range, 70-83 years) and median ECOG PS was 1 (range, 0-1). patients received carboplatin (AUC=2) and paclitaxel 80 mg/m² on days 1,8 and 15 every 28 days. All patients were evaluable for efficacy and toxicity; a median of 4 cycles was administered. Twelve patients had partial response (33%; 95% C.I. 15,8-52,3%), 10 patients (28%) showed stable disease. The median time to progression (TTP) was 5.7 months (95% C.I. 3.1-8.6 months) with a median overall survival (MOS) of 9 months (95% C.I. 4.4-13.9 months). Toxicity was mild with no cases of febrile neutropenia; 5 patients (14%) developed grade 2 neuropathy. Our study confirms the substantial activity of weekly regimen of paclitaxel and carboplatin. Due to its favorable profile of toxicity this schedule could represent an interesting therapeutic option in selected chemonaive elderly patients with advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|